I-Mab financial data

Symbol
IMAB on Nasdaq
Industry
Pharmaceutical Preparations
Location
Suite 400, 2440 Research Blvd, Rockville, Maryland
State of incorporation
Cayman Islands
Fiscal year end
December 31
Latest financial report
Q4 2023 - Apr 30, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 186M shares -2.76%
Common Stock, Shares, Outstanding 186M shares -2.76%
Common Stock, Value, Issued 19K USD 0%
Weighted Average Number of Shares Outstanding, Basic 191M shares +0.86%
Weighted Average Number of Shares Outstanding, Diluted 191M shares +0.86%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 3.89M USD
Cost of Revenue 3.95M USD -45.8%
Research and Development Expense 114M USD -13%
General and Administrative Expense 63.8M USD -46.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -206M USD +43.2%
Income Tax Expense (Benefit) 101K USD
Net Income (Loss) Attributable to Parent -206M USD +43.2%
Earnings Per Share, Basic -1.08 USD/shares +43.8%
Earnings Per Share, Diluted -1.08 USD/shares +43.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 302M USD -35.3%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Inventory, Net 0 USD -100%
Assets, Current 329M USD -37.4%
Property, Plant and Equipment, Net 5.14M USD -41.7%
Operating Lease, Right-of-Use Asset 6.54M USD -28.6%
Intangible Assets, Net (Excluding Goodwill) 16.6M USD -3.49%
Goodwill 23.6M USD -7.61%
Other Assets, Noncurrent 603K USD -61.9%
Assets 368M USD -37.7%
Employee-related Liabilities, Current 6.85M USD +8.6%
Contract with Customer, Liability, Current 310K USD -75.4%
Liabilities, Current 58M USD -47.2%
Contract with Customer, Liability, Noncurrent 41.1M USD +5.94%
Operating Lease, Liability, Noncurrent 3.25M USD -30%
Other Liabilities, Noncurrent 9.81M USD +299%
Liabilities 126M USD -25.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 42M USD +35.5%
Retained Earnings (Accumulated Deficit) -1.17B USD -17.9%
Stockholders' Equity Attributable to Parent 242M USD -42.6%
Liabilities and Equity 368M USD -37.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -184M USD -15%
Net Cash Provided by (Used in) Financing Activities 1.07M USD -82.6%
Net Cash Provided by (Used in) Investing Activities 14.4M USD -78.3%
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 186M shares -2.76%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -156M USD -407%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 310M USD -33.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 99K USD
Deferred Tax Assets, Valuation Allowance 168M USD +22.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 6.34M USD -22%
Depreciation 3.37M USD -8.19%
Payments to Acquire Property, Plant, and Equipment 1.6M USD -75.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -195M USD +36.3%
Lessee, Operating Lease, Liability, to be Paid 7.04M USD -40%
Property, Plant and Equipment, Gross 15.5M USD -8.04%
Operating Lease, Liability, Current 3.08M USD -11.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 873K USD -77.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.23M USD -41.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 705K USD -80.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 898K USD +19.3%
Deferred Tax Assets, Operating Loss Carryforwards 128M USD +11.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 924K USD +20.5%
Operating Lease, Payments 3.11M USD -39.9%
Amortization of Intangible Assets 110K USD -2.66%
Depreciation, Depletion and Amortization 3.4M USD -8.11%
Deferred Tax Assets, Net of Valuation Allowance 2.5M USD -3.48%
Share-based Payment Arrangement, Expense 27.9M USD -48.2%
Interest Expense 102K USD +10100%